Introduction
============

Hepatocellular carcinoma (HCC) is the fifth-most common malignancy and the third-leading cause of cancer deaths worldwide.[@b1-ott-11-689] HCC is an aggressive cancer associated with poor survival, frequent recurrence, and metastases after surgical resection or chemotherapy.[@b2-ott-11-689] Moreover, most patients are diagnosed with highly invasive, unresectable HCC, and have poor outcomes. Although advanced diagnostics and new treatments have been developed, how HCC progresses is not clear.[@b3-ott-11-689] As such, there is an urgent need to identify novel biomarkers to improve patient prognosis.

Zwint, a centromere-complex component required for the mitotic spindle checkpoint, is involved in centromere function and cell growth.[@b4-ott-11-689] Most studies have suggested that Zwint interacts with Zw10, another centromere protein, possibly regulating the association between Zw10 and centromeres. Zwint is reported to be required for spindle-assembly checkpoint function.[@b5-ott-11-689] In addition, Zwint has been shown to be a part of the MIS12 complex and interacts with Rab3C.[@b6-ott-11-689]--[@b8-ott-11-689] Endo et al demonstrated that Zwint depletion by Terf/Trim17 negatively regulated cell proliferation in 293T cells and breast cancer MCF7 cells.[@b9-ott-11-689] Seo et al reported that Zwint was required to correct erroneous centromere-microtubule attachment and regulate spindle-checkpoint function during meiosis.[@b10-ott-11-689] Recently, overexpression of Zwint has been reported in human malignancies, including prostate, ovarian, bladder, and breast cancers, as well as pulmonary adenocarcinoma and ependymomas.[@b11-ott-11-689]--[@b16-ott-11-689] Aberrant expression of Zwint is associated with chromosome-instability signatures and poor prognosis in primary tumors.[@b17-ott-11-689] These new findings encourage further investigation of Zwint's potential clinical significance in human malignancies.

Because the expression and clinical significance of Zwint has not been studied in human HCC, we performed searches and survival analyses of Zwint on microarray data sets from the Oncomine ([www.oncomine.com](http://www.oncomine.com)) and The Cancer Genome Atlas (TCGA) databases. We examined *ZWINT* mRNA and protein expression in HCC clinical samples and analyzed correlations of Zwint expression with various clinical and pathological parameters. In addition, we explored the role of Zwint in regulating cell proliferation in vivo and in vitro. Our results showed that Zwint increases tumor growth and may be a novel prognostic marker in HCC.

Materials and methods
=====================

Ethics approval and informed consent
------------------------------------

The study was verified and ethically approved by the Medical Ethics Committee of Sir Run Run Shaw Hospital (SRRSH), College of Medicine, Zhejiang University. All patients provided written informed consent for the use of surgical specimens for pathological testing with operation consents. As such, the Medical Ethics Committee of (SRRSH) decided that the study of patient tissue for future research was ethically acceptable without special informed consent. Patient privacy is well protected, and no personal information is disclosed in this article. All animal care and experimental procedures were in strict accordance with recommendations in the Guide for the Care and Use of Laboratory Animals, and were approved by the Committee on the Ethics of Animal Experiments of Zhejiang Chinese Medical University (permit ZSLL-2017-096).

Patients and specimens
----------------------

Formalin-fixed paraffin-embedded tissue samples from 106 HCC patients who had received curative surgery in SRRSH from January 2006 to December 2010 were included. Clinical and pathological characteristics of the cohort are listed in [Table 1](#t1-ott-11-689){ref-type="table"}. Tumor stages were graded according to the seventh edition of the American Joint Committee on Cancer staging system.[@b18-ott-11-689] Tumor differentiation was classified according to the Edmondson--Steiner grading system, and clinical stages were defined based on the Barcelona Clinic Liver Cancer (BCLC) staging system.[@b18-ott-11-689],[@b19-ott-11-689] Patients were followed for 6 years.

A set of 37 paired fresh-frozen HCC samples obtained from patients who had received surgery in our hospital from August 2014 to December 2015 were used for quantitative polymerase chain reaction (PCR) analysis. For Western blot, 20 paired fresh-frozen HCC samples and corresponding noncancerous samples were obtained from HCC patients undergoing hepatectomy from January 2015 to June 2015 in SRRSH.

Roessler liver microarray (250 HCC samples and 220 normal livers), Wurmbach liver microarray (35 HCC samples and ten normal livers) and Chen liver microarray (74 HCC samples and 104 normal livers) were collected from Oncomine. mRNA expression from 374 HCC tissues was obtained from the publicly available TCGA database, and the survival rate (364 patients with follow-up information) was analyzed by the Gene Expression Profiling Interactive Analysis website (<http://gepia.cancer-pku.cn>), a network analyzing TCGA data online.[@b28-ott-11-689]

Cell culture
------------

The human HCC cell lines Huh7, HepG2, HCCLM3, Hep3B and normal hepatic cell line L02 were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). HCCLM3, Huh7, Hep3B, and L02 cells were cultured in DMEM (Thermo Fisher Scientific, Waltham, MA, USA) with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific). HepG2 cells were cultured in MEM (Thermo Fisher Scientific) with 10% FBS (Thermo Fisher Scientific). Cells were maintained at 37°C in 5% CO~2~.

Plasmid construction and cell infection
---------------------------------------

A lentivirus-based Zwint RNA plasmid (sh*ZWINT*) and a nonspecific shRNA plasmid (Scrambled) were constructed (GeneChem, Shanghai, China). The *ZWINT* gene was cloned in pWPI plasmids. pWPI-Zwint and pWPI-vector plasmids were transfected into 293T cells with a mixture of pWPI, PAX2 (viral packaging plasmid), and pMD2G (envelope plasmid) at a 4:3:2 ratio using Lipofectamine 2000 (Thermo Fisher Scientific). Lentiviral supernatants were then collected to infect HCC cells. Stable cells were selected and confirmed by quantitative real-time (qRT) PCR and Western blotting.

Quantitative real-time PCR analysis
-----------------------------------

Total RNA from tissue samples and cells were extracted using Trizol reagent (Thermo Fisher Scientific) according to the manufacturer's instructions. cDNA was synthesized from 1 μg RNA of each sample using an iScript cDNA-synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA). qRT-PCR was performed using a 7500 RT-PCR system (Thermo Fisher Scientific). Zwint primer sequences were: forward 5′-AGGACACTGCTAAGGGTCTCG-3′, reverse 5′-GCCTCTACGTGCTCCCTGTA-3′. Cyclin B1 primer sequences were: forward 5′-AACTTTCGCCTGAGCCTATTTT-3′, reverse 5′-TTGGTCTGACTGCTTGCTCTT-3′. PCNA primer sequences were: forward 5′-CCTGCTGGGATATTAGCTCCA-3′, reverse 5′-CAGCGGTAGGTGTCGAAGC-3′. CDK1 primer sequences were: forward 5′-GGATGTGCTTATGCAGGATTCC-3′, reverse 5′-CATGTACTGACCAGGAGGGATAG-3′. GAPDH primer sequences were: forward 5′-ACAACTTTGGTATCGTGGAAGG-3′, reverse 5′-GCCATCACGCCACAGTTTC-3′. Each sample was tested in triplicate. Data were analyzed using the ΔΔCt method.

Western blot
------------

Cells were harvested and washed twice with cold PBS, then resuspended and lysed in radioimmunoprecipitation-assay buffer (1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 10 ng/mL phenylmethylsulfonyl fluoride, 0.03% aprotinin, 1 μM sodium orthovanadate) at 4°C for 30 minutes. Lysates were centrifuged for 10 minutes at 14,000× *g* and supernatants quantified with a Pierce BCA protein-assay kit (Thermo Fisher Scientific). Protein was separated by 10% sodium dodecyl sulfate polyacrylamide-gel electrophoresis. Samples were transferred to polyvinylidene difluoride membranes (Merck Millipore, Billerica, MA, USA) and incubated overnight at 4°C with the primary antibodies Zwint (1:1,000, AP6686c; Abgent, San Diego, CA, USA), Cdc25C (1:1,000, ab32444; Abcam, Cambridge, UK), cyclin B1 (1:1,000, CST 4138), CDK1 (1:1,000, ab133327; Abcam), PCNA (1:1,000, CST 13110S), and GAPDH (1:1,000, G5262; Sigma-Aldrich, St Louis, MO, USA). After incubation with HRP-coupled anti-mouse IgG antibody (1:2,000, Beyotime, Haimen, China) at 37°C for 2 hours, target proteins on polyvinylidene difluoride membranes were visualized using Clarity Western ECL substrate (Bio-Rad) and captured using a luminescent-image analyzer (FujiFilm, Tokyo, Japan).

Immunohistochemical analysis
----------------------------

Immunohistochemistry (IHC) was used to evaluate Zwint expression in 106 paired HCC samples and corresponding noncancerous samples. Primary antibodies for Zwint (1:400, AP6686c) were incubated overnight at 4°C. Normal goat serum was used as a negative control. Expression of Zwint was then measured using a GTVision III detection system (Gene Tech, Shanghai, China). Diaminobenzidine visualization was then performed. Immunostaining was evaluated and scored by two pathologists without prior knowledge of clinicopathological data using a German immunoreactive score.[@b20-ott-11-689] Intensity was assessed as 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). Scores representing percentage of tumor cells positively stained were 0 (\<5%), 1 (5%--25%), 2 (25%--50%), 3 (50%--75%), or 4 (\>75%). Staining-intensity values and staining extent were multiplied as a final immunoreactive score of Zwint expression with scores of 0, 1, 2, 3, 4, 6, 8, 9, or 12. A score ≥6 was used to define tumors with high Zwint expression and a score ≤4 indicated low Zwint expression.

Cell-proliferation assay
------------------------

Stable transfected cells (3×10^3^ for HCCLM3 and Huh7, 5×10^3^ for HepG2) were seeded on 96-well plates with three replicate wells and allowed to incubate for 24 hours. After incubation, cell viability was assessed at 0, 24, 48, 72 and 96 hours using a cell counting kit-8 (CCK-8) protocol (Dojindo, Kumamoto, Japan). All experiments were performed at least in triplicate on three separate occasions.

Plate colony-formation assay
----------------------------

For colony-formation assays with monolayer cultures, HCCLM3 cells were seeded at 300 cells/well in six-well plates with Zwint shRNA plasmid and Zwint Scramble plasmid. HepG2 cells were seeded at 600 cells/well in six-well plates with pWPI-Zwint and pWPI-vector plasmids. After 14 days of culture, cell colonies (≥50 cells/colony) were counted after staining with 0.5% crystal violet.

Cell-cycle analysis
-------------------

Cell-cycle distribution was determined by flow cytometry according to the manufacturer's instructions for the cell-cycle staining buffer (MultiSciences CCS01). Cells were detected with a FACSCalibur.

Tumor-formation assay in nude mice
----------------------------------

BALB/c nude mice (n=12, 4 weeks of age) were obtained from Shanghai Laboratory Animal Center and housed in the laboratory-animal research center of Zhejiang Medical University. Cultures of HCCLM3 cells for control and sh*ZWINT* groups were resuspended with PBS. Mice were randomized and treated with HCCLM3/sh*ZWINT* (6×10^6^, subcutaneous) or control in 150 μL of PBS (n=6/group). After 10 days, growth of implanted tumors was monitored using Vernier calipers every 5 days: All mice were sacrificed after 30 days. $$\text{Tumor~volume}\ (\text{cm}^{3}) = 0.5 \times \text{Tumor~length}\ (\text{cm}) \times \text{Tumor~width}^{2}(\text{cm}^{2})$$

All mice were sacrificed after 30 days.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS 18.0 software (SPSS Inc, Chicago, IL, USA). GraphPad Prism 6 software (San Diego, CA, USA) was used to perform graphical representations. Associations between Zwint and clinical features were analyzed using Pearson's *χ*^2^ or Fisher's exact test. Survival data were analyzed with Kaplan--Meier survival curves and log-rank test. Univariate and multivariate Cox proportional-hazard models were used to evaluate the effect of each variable on survival. Correlations of expression of Zwint and PCNA, cyclin B1, Cdc25C, and CDK1 were analyzed using bivariate correlation analysis. Scatterplots with regression lines confirmed correlations using Pearson's correlation coefficient. All results of experiments are expressed as means ± SD. Statistical analysis of differences between treated and untreated groups was performed with Student's *t*-test, and *P*\<0.05 was considered significant.

Results
=======

Overexpression of Zwint in HCC tissues and cell lines
-----------------------------------------------------

Analysis of multiple microarray data sets in the Oncomine and TCGA databases confirmed that *ZWINT* mRNA was significantly increased in HCC tissues compared to adjacent normal liver tissues in Roessler ([Figure 1A](#f1-ott-11-689){ref-type="fig"}), Wurmbach ([Figure 1B](#f1-ott-11-689){ref-type="fig"}), and Chen liver data sets ([Figure 1C](#f1-ott-11-689){ref-type="fig"}). *ZWINT* mRNA expression from 37 paired fresh-frozen HCC tissues was significantly increased compared to corresponding noncancerous tissues (*P*\<0.01, [Figure 1D](#f1-ott-11-689){ref-type="fig"}). Upregulation of *ZWINT* mRNA occurred in most cases ([Figure 1E](#f1-ott-11-689){ref-type="fig"}). Upregulated *ZWINT* was associated with shortened patient survival (*P*=0.00061, [Figure 1F](#f1-ott-11-689){ref-type="fig"}). Zwint protein was measured in HCC samples and corresponding adjacent normal liver specimens with Western blot or IHC staining. [Figure 2](#f2-ott-11-689){ref-type="fig"} shows that most HCC samples had elevated Zwint protein ([Figure 2A and C](#f2-ott-11-689){ref-type="fig"}), and Zwint expression in four HCC cell lines and a normal human L02 liver cell line confirmed that Zwint expression was greater in HCC cell lines ([Figure 2B](#f2-ott-11-689){ref-type="fig"}).

Correlation of Zwint expression with HCC clinicopathologic features
-------------------------------------------------------------------

IHC data for Zwint expression in 106 pairs of HCC tissues and adjacent normal tissues were classified as described in the Materials and methods section. [Figure 3A](#f3-ott-11-689){ref-type="fig"} shows different staining-intensity levels of tissue samples and that there was a statistically significant difference in Zwint expression between HCC and normal tissue (*P*\<0.001, [Figure 3B](#f3-ott-11-689){ref-type="fig"}). Fisher's exact or *χ*^2^ test was used to analyze correlations between Zwint protein expression and clinicopathologic variables, and high Zwint expression was significantly correlated with tumor size (*P*=0.025) and tumor number (*P*=0.035). However, Zwint overexpression was not associated with other features, as described in [Table 1](#t1-ott-11-689){ref-type="table"}.

Prognostic values of Zwint expression for HCC patients
------------------------------------------------------

Kaplan--Meier analysis and log-rank test were used to assess the association between Zwint expression and 106 patients' prognoses, and [Figure 4](#f4-ott-11-689){ref-type="fig"} shows that 5-year overall and disease-free survival were shorter with high Zwint expression (*P*=0.001, [Figure 4A](#f4-ott-11-689){ref-type="fig"}) and this was also associated with more tumor recurrence (*P*=0.005, [Figure 4B](#f4-ott-11-689){ref-type="fig"}). Median survival time was shorter with high Zwint expression (67 months versus 55 months). Stratified survival analysis to evaluate prognostic significance showed that for tumor size ≤5 cm, high expression of Zwint predicted poor overall survival (*P*=0.005, [Figure 4C](#f4-ott-11-689){ref-type="fig"}) and disease-free survival (*P*=0.008, [Figure 4D](#f4-ott-11-689){ref-type="fig"}). Similarly, high expression of Zwint significantly predicted poor overall survival (*P*=0.013, [Figure 4E](#f4-ott-11-689){ref-type="fig"}) and disease-free survival (*P*=0.022, [Figure 4F](#f4-ott-11-689){ref-type="fig"}) in patients with single tumors.

Cox regression analysis of evaluated independent risk factors was used, and univariate analysis showed that tumor size, tumor thrombi, TNM stage, and BCLC stage were significantly associated with overall and disease-free survival. Multivariate analysis showed that Zwint was an independent prognostic indicator of overall survival (*P*=0.003) and disease-free survival (*P*=0.022) ([Table 2](#t2-ott-11-689){ref-type="table"}).

Zwint promoted HCC-cell proliferation
-------------------------------------

Zwint upregulation was associated with tumor size and number, so Zwint may promote proliferation of HCC cells. shRNA knockdown of endogenous *ZWINT* in HCCLM3 and Huh7 cells was performed, and Zwint plasmid was used to express *ZWINT* mRNA and protein in HepG2 cells ([Figure 5A and B](#f5-ott-11-689){ref-type="fig"}). A CCK-8 assay ([Figure 5C](#f5-ott-11-689){ref-type="fig"}) showed that cell proliferation was significantly suppressed by *ZWINT* shRNA in HCCLM3 and Huh7 cells, and this was enhanced by ectopic expression of Zwint in HepG2 cells. Similarly, *ZWINT* knockdown attenuated clone formation for HCCLM3 and Huh7 cells, whereas *ZWINT* overexpression promoted clone formation in HepG2 cells (clones increased, [Figure 5D](#f5-ott-11-689){ref-type="fig"}).

*ZWINT* knockdown arrested HCC cell cycle in G~2~/M phase
---------------------------------------------------------

Zwint protein's effect on the cell cycle was analyzed with flow cytometry after propidium iodide staining and [Figure 6A](#f6-ott-11-689){ref-type="fig"} shows that *ZWINT* knockdown significantly increased the proportion of HCCLM3 cells in the G~2~/M phase. Ectopic expression of Zwint decreased the proportion of HepG2 cells in the G~2~/M phase.

*ZWINT* knockdown decreased the expression of cell-cycle proteins
-----------------------------------------------------------------

To elucidate the mechanism of cell-cycle arrest by *ZWINT* knockdown, we studied correlations between *ZWINT* mRNA expression and multiple genes with essential roles in the G~2~/M phase using the microarray data from 374 HCC tissues from the TCGA database. *ZWINT* expression was significantly correlated with *PCNA* (*P*\<0.001, *R*=0.691), *CDC25C* (*P*\<0.001, *R*=0.814), cyclin B1 (*P*\<0.001, *R*=0.837), and *CDK1* expression (*P*\<0.001, *R*=0.909) ([Figure 6C](#f6-ott-11-689){ref-type="fig"}). Furthermore, PCNA, cyclin B1, Cdc25C and CDK1 protein quantified using Western blot ([Figure 6B](#f6-ott-11-689){ref-type="fig"}) showed that all were decreased in HCCLM3 cells after *ZWINT* knockdown and that these increased in HepG2 cells that overexpressed *ZWINT*.

*ZWINT* knockdown inhibited tumor growth in vivo
------------------------------------------------

*ZWINT* knockdown decreased the proliferation of HCCLM3 cells in vitro, and this was confirmed in vivo using a stable HCCLM3 cell line for sh*ZWINT* with Scrambled shRNA used as a control. sh*ZWINT* decreased expression of Zwint and Ki67 compared with controls ([Figure 7C--E](#f7-ott-11-689){ref-type="fig"}). After the model had been established, tumors were completely removed 30 days later and imaged ([Figure 7A](#f7-ott-11-689){ref-type="fig"}). *ZWINT* knockdown decreased tumor volumes ([Figure 7B](#f7-ott-11-689){ref-type="fig"}), and qRT-PCR and Western blotting showed that *ZWINT* knockdown blocked expression of PCNA, cyclin B1, and CDK1 compared with controls.

Discussion
==========

Zwint was initially identified as an additional centromere-associated protein in a yeast two-hybrid screen for proteins that interact with Zw10, regulating the mitotic spindle checkpoint.[@b4-ott-11-689] Knockdown of *ZWINT* disrupts localization of the RZZ complex (Rod, Zw10, and Zwilch) to centromeres and impairs checkpoint activity.[@b5-ott-11-689],[@b21-ott-11-689],[@b22-ott-11-689] Recently, Zwint was found to interact with the KMN network (Knl1, Mis12, and Ndc80) and appeared to connect the KMN network and the RZZ complex. This connection (KMN--Zwint--RZZ) is important for transferring signals from Aurora B to the spindle-assembly checkpoint.[@b6-ott-11-689],[@b23-ott-11-689]--[@b25-ott-11-689] *ZWINT* is a gene that is overexpressed in pulmonary adenocarcinoma.[@b11-ott-11-689] Endoh et al reported that high expression of Zwint was related to poor survival in pulmonary adenocarcinoma.[@b16-ott-11-689] Brendle et al found that Zwint might affect breast cancer risk and clinical outcomes.[@b26-ott-11-689] Zwint could be upregulated by overexpression of androgen receptors in prostate cancer.[@b15-ott-11-689] Xu et al recently demonstrated that *ZWINT* mRNA is frequently overexpressed in ovarian cancer, and may be a biomarker to support early diagnosis and evaluate prognosis.[@b14-ott-11-689] These results indicate that Zwint may be significant in cancer and may be a potential target for cancer diagnosis and treatment. Even so, the correlation of Zwint and HCC has not been assessed.

We report that expression of Zwint is upregulated in HCC and may be used to predict tumor progression and unfavorable prognosis of HCC patients. First, we collected information about Zwint expression from the Oncomine database. Two independent data sets showed that *ZWINT* mRNA was increased in HCC tissue compared with normal liver tissue. Data from a group of 364 HCC patients with information about mRNA expression and prognosis was obtained from the TCGA database using bioinformatic analysis, and high expression of Zwint predicted a poor rate of survival. Then, with qRT-PCR and Western blot analysis, we found that Zwint was overexpressed in HCC samples and HCC cell lines. Data support previous findings about upregulated *ZWINT* mRNA expression in human cancers.

Furthermore, our IHC analysis of 106 paired HCC samples confirmed that the Zwint protein was significantly upregulated in HCC; 55.6% of cancerous tissue had moderate or high expression, whereas only 21.7% of adjacent noncancerous tissue had similar results with the IHC. Of note, significant differences were observed with qRT-PCR (86.5%) and Western blotting (90%) in cancerous tissues. This discrepancy may have been related to the number of HCC samples. Therefore, our results confirmed that Zwint is significantly upregulated in HCC.

A more important finding of our study was a correlation of clinicopathologic features and the prognostic value of Zwint expression in HCC. High expression of Zwint was significantly correlated with tumor size and number, indicating that Zwint may be a biomarker to evaluate the progression of HCC patients. In addition, we observed a significant association between increased Zwint protein and poor survival and high recurrence of HCC. Univariate and multivariate survival analysis showed that increased Zwint expression was significantly associated with overall and disease-free survival, and was an independent risk factor for poor survival and high recurrence in HCC patients. Tumor characteristics, such as tumor number and size, are important for progression and prognosis of HCC, and patients at the same clinical stage may have different outcomes.[@b27-ott-11-689] Therefore, we performed a stratified survival analysis, and demonstrated that high expression of Zwint also predicted poor overall survival and disease-free survival for patients with ≤5 cm tumors and single tumors. Therefore, results from our study suggest that Zwint expression may be a biomarker to predict prognosis in HCC patients. This may also be used to classify patients into distinct risk subgroups, as well as serve as a novel therapeutic target of HCC.

It has been documented that Zwint is required for spindle-assembly checkpoint function. Downregulation of Zwint may induce Zw10 centromere instability and negatively regulate cell proliferation in 293T and breast cancer cells. To analyze the biological function of Zwint, we knocked down or overexpressed *ZWINT* in HCC cells. Proliferation, clone formation, and the cell cycle were reduced with sh*ZWINT*, whereas these functions increased in HCC cells over-expressing *ZWINT*. Cell-cycle studies in HCC cells confirmed that there were more cells in the G~2~/M phase, whereas cells in the G~1~ or S phase were reduced. Multiple genes that regulate the G~2~/M phase were assayed using mRNA-expression data from 374 HCC samples from the TCGA database. Zwint expression was significantly correlated with PCNA, Cdc25C, cyclin B1, and CDK1 expression. PCNA, Cdc25C, cyclin B1, and CDK1 proteins were also positively regulated in HCC cell lines that were studied, with downregulated or upregulated Zwint expression. Therefore, expression of Zwint might contribute to the HCC cell cycle by regulating the G~2~/M phase. However, how Zwint and cell-cycle proteins interact is not clear, and more studies are required.

In conclusion, we showed that expression of Zwint was frequently upregulated in HCC tissues and HCC cell lines. High expression of Zwint was significantly associated with tumor progression and poor prognosis of HCC patients. In HCC cell lines, depletion of Zwint may attenuate proliferation and cell-cycle progression of HCC cells, but our study was limited in many ways. We did find a correlation between Zwint and cell-cycle proteins, but how Zwint affects proliferation and the cell cycle is not clear. As such, Zwint might be a novel biomarker for HCC progression and prognosis, but more studies are required to validate this preliminary data and clarify a role for Zwint in HCC.
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![Expression of *ZWINT* in HCC at mRNA level.\
**Notes:** (**A**--**C**) Upregulated *ZWINT* mRNA expression compared with normal liver tissue in Roessler, Wurmbach, and Chen liver data sets from the Oncomine database. (**D**) mRNA level in 37 paired HCC-tissue samples. *ZWINT* expression was elevated in HCC tissue (*P*\<0.01). (**E**) *ZWINT* mRNA levels in 37 paired HCC-tissue samples. *ZWINT* mRNA level expressed as log~2~(T/N). Log~2~(T/N) \<0 represents the downregulation of *ZWINT* in tumor tissue. Log~2~(T/N) \>0 represents the upregulation of *ZWINT* in tumor tissue. (**F**) Based on the TCGA database and analyzed by the Gene Expression Profiling Interactive Analysis website (<http://gepia.cancer-pku.cn>), a network analyzing TCGA data online, high expression of *ZWINT* predicted a poor survival rate in 364 HCC patients.\
**Abbreviations:** HCC, hepatocellular carcinoma; T, tumor tissue; N, noncancerous tissue; TCGA, The Cancer Genome Atlas; TPM, transcripts per (kilobase) million; HR, hazard ratio.](ott-11-689Fig1){#f1-ott-11-689}

![Expression of Zwint protein in HCC tissue and cell lines.\
**Notes: (A)** Protein expression in 20 HCC tissue samples and paired adjacent noncancerous tissue samples was determined by Western blot analysis. GAPDH was used as a loading control. (**B**) Protein expression of HCC cell lines and L02, a normal liver cell line. (**C**) Immunohistochemical staining of Zwint protein expression in HCC tissue and adjacent noncancerous tissue. The region in the white box is enlarged in the image in [Figure 3](#f3-ott-11-689){ref-type="fig"}.\
**Abbreviations:** HCC, hepatocellular carcinoma; T, tumor tissue; N, noncancerous tissue.](ott-11-689Fig2){#f2-ott-11-689}

![Immunostaining of Zwint protein in human HCC and adjacent normal tissues.\
**Notes:** (**A**) Representative immunohistochemical expression patterns of Zwint in cancerous and adjacent normal tissue; (**B**) percentage of cases with different staining intensity of Zwint in the tumor or adjacent noncancerous tissue in the study cohort. (n=106, *P*\<0.001).\
**Abbreviations:** HCC, hepatocellular carcinoma; T, tumor tissue; N, noncancerous tissue.](ott-11-689Fig3){#f3-ott-11-689}

![Kaplan--Meier survival analysis for HCC patients and subgroups.\
**Notes:** (**A**, **B**) Kaplan--Meier curves for overall survival and disease-free survival of all HCC patients according to Zwint-expression status (n=106); (**C**, **D**) Kaplan--Meier curves for overall survival and disease-free survival of HCC patients with tumor size ≤5 cm according to Zwint-expression status (n=64); (**E**, **F**) Kaplan--Meier curves for overall survival and disease-free survival of HCC patients with single tumors according to Zwint-expression status (n=93). *P*-values determined using log-rank tests.\
**Abbreviation:** HCC, hepatocellular carcinoma.](ott-11-689Fig4){#f4-ott-11-689}

###### 

Effect of Zwint on proliferation of HCC cells.

**Notes:** (**A**) Zwint protein levels were detected in HCCLM3 and Huh7 cells with transfected sh*ZWINT* and HepG2 cells with transfected Zwint plasmid. (**B**) *ZWINT* mRNA expression detected in HCCLM3, Huh7, and HepG2 cells. (**C**) Cell growth of HCCLM3, Huh7, and HepG2 with sh*ZWINT* or Zwint plasmid determined by CCK-8 assay at different time points. (**D**) Knockdown of *ZWINT* suppressed cell growth of HCCLM3 and Huh7 in formation assays, and overexpressed *ZWINT* increased cell growth of HepG2. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001.

**Abbreviations:** HCC, hepatocellular carcinoma; CCK-8, cell counting kit-8.
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###### 

Effect of *ZWINT* on the cell cycle.

**Notes:** (**A**) Knocking down *ZWINT* induced G~2~/M-phase arrest in HCCLM3, and upregulated *ZWINT* promoted the G~2~/M phase in HepG2 cell lines. All fluorescence-activated cell-sorting images representative of at least three independent experiments. The graphs at the right show quantification of the band intensity. (**B**) Protein levels of Zwint, PCNA, CDK1, cyclin B1, and Cdc25C in HCC cells with *ZWINT* knockdown. (**C**) Correlation between mRNA expression of *ZWINT* and PCNA, CDK1, cyclin B1 and Cdc25C. mRNA expression of 374 HCC patients from TCGA database. \**P*\<0.05.

**Abbreviations:** HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas.
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![*ZWINT* knockdown inhibited tumor formation in vivo in nude mice.\
**Notes:** (**A**) After 30 days, all nude mice were sacrificed and tumors separated. (**B**) Tumor volume calculated every 5 days (n=6). (**C**) mRNA expression of *ZWINT*, *PCNA*, cyclin B1 and *CDK1* in tumor tissue of control and sh*ZWINT* groups (means ± standard error of the mean). (**D**) Western blot shows protein expression of Zwint, PCNA, cyclin B1, and CDK1. (**E**) Immunohistochemistry images of Zwint and Ki67 expression in control and sh*ZWINT* groups. \**P*\<0.05; \*\**P*\<0.01.\
**Abbreviation:** HCC, hepatocellular carcinoma.](ott-11-689Fig7){#f7-ott-11-689}

###### 

Association between Zwint expression and clinicopathologic characteristics of HCC patients (n=106)

                              Cases   Zwint expression   *P*-value[\*](#tfn1-ott-11-689){ref-type="table-fn"}   
  --------------------------- ------- ------------------ ------------------------------------------------------ ------------------------------------------------------
  Total                       106     47 (44.3)          59 (55.7)                                              
  **Age (years)**                                                                                               0.199
  \<60                        49      25 (53.2)          24 (40.7)                                              
  ≥60                         57      22 (46.8)          35 (59.3)                                              
  **Sex**                                                                                                       0.596
  Male                        88      38 (80.8)          50 (84.7)                                              
  Female                      18      9 (19.2)           9 (15.3)                                               
  **HBsAg**                                                                                                     0.253
  Negative                    16      5 (10.6)           11 (18.6)                                              
  Positive                    90      42 (89.4)          48 (81.4)                                              
  **AFP (ng/mL)**                                                                                               0.767
  \<400                       66      30 (63.8)          36 (61)                                                
  ≥400                        40      17 (36.2)          23 (39)                                                
  **Liver cirrhosis**                                                                                           0.582
  No                          46      19 (40.4)          27 (45.8)                                              
  Yes                         60      28 (59.6)          32 (54.2)                                              
  **Tumor size**                                                                                                **0.025**[\*](#tfn1-ott-11-689){ref-type="table-fn"}
  ≤5 cm                       64      34 (72.3)          30 (50.8)                                              
  \>5 cm                      42      13 (27.6)          29 (49.2)                                              
  **Tumor number**                                                                                              **0.035**[\*](#tfn1-ott-11-689){ref-type="table-fn"}
  Single                      93      45 (95.7)          48 (81.4)                                              
  Multiple                    13      2 (4.3)            11 (18.6)                                              
  **Tumor differentiation**                                                                                     0.134
  Good/moderate               56      21 (44.7)          35 (59.3)                                              
  Poor                        50      26 (55.3)          24 (40.7)                                              
  **Tumor thrombi**                                                                                             0.647
  No                          92      40 (85.1)          52 (88.1)                                              
  Yes                         14      7 (14.9)           7 (11.9)                                               
  **TNM stage**                                                                                                 0.507
  I + II                      96      44 (93.6)          52 (88.1)                                              
  III + IV                    10      3 (6.4)            7 (11.9)                                               
  **BCLC stage**                                                                                                1
  A                           96      43 (91.5)          53 (89.8)                                              
  B                           10      4 (8.5)            6 (10.2)                                               

**Notes:**

Pearson chi-square test or Fisher exact test was used for comparison between subgroups. Significant results (*P*\<0.05) are given in bold.

**Abbreviations:** HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; BCLC, Barcelona Clinic Liver Cancer.

###### 

Prognostic factors for OS and DFS of HCC patients (n=106)

                                            OS      DFS                                                 
  ----------------------------------------- ------- ------- ----- ------------ --------- ------- ------ -----------
  Age (years), \<60/≥60                     0.387                              0.118                    
  Sex                                       0.727                              0.399                    
  HBsAg (negative/positive)                 0.577                              0.805                    
  AFP (ng/mL), \<400/≥400                   0.312                              0.984                    
  Liver cirrhosis (no/yes)                  0.78                               0.338                    
  Tumor size (cm), \<5/≥5                   0.009                              0.001     0.009   2.08   1.2--3.6
  Tumor number (single/multiple)            0.705                              0.177                    
  Tumor differentiation (I + II/III + IV)   0.367                              0.89                     
  Tumor thrombi (no/yes)                    0.049                              \<0.001   0.011   3.18   1.31--7.7
  TNM stage (I + II/III + IV)               0.004                              0.004                    
  BCLC stage (A/B)                          0.002                              \<0.001                  
  Zwint (low/high)                          0.004   0.003   3.1   1.45--6.61   0.021     0.022   1.88   1.1--3.22

**Abbreviations:** OS, overall survival; DFS, disease-free survival; HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; BCLC, Barcelona Clinic Liver Cancer; HR, hazard ratio.
